Abstract:Xinkai Luo, 1, &ast Ying Wang, 2, &ast Yufei Mao, 3, &ast Xiaowei Xu, 1, 4 Weifeng Gu, 1 Wen Li, 1 Chaoming Mao, 1 Tingting Zheng, 1 Liyang Dong 1 1 Department of Nuclear Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China; 2 Department of Respiratory Diseases, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, Jiangsu, People's Republic of China; 3 Department of Ultrasound Medicine, The Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu, People's Republic of China; 4 Department of Laboratory Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liyang Dong; Tingting Zheng, Email ; Background: Nebulization of hypoxic human umbilical cord mesenchymal stem cell-derived extracellular vesicles (Hypo-EVs) can suppress airway inflammation and remodeling in a chronic asthmatic mouse; however, the exact mechanism remains unclear. Recently, airway epithelial barrier defects have been regarded as crucial therapeutic targets in asthma. The aim of this study was to investigate whether and how Hypo-EVs protect against the disruption of the airway epithelial barrier under asthmatic conditions. Methods: The therapeutic effects of Hypo-EVs on airway epithelial barrier defects were evaluated in ovalbumin (OVA)-induced asthmatic mice and in IL-4 and IL-13-induced HBE135-E6E7 cell models by detecting cell monolayer leakage and junctional protein expression. The protein levels in Hypo-EVs were determined by Western blotting, and a gene knockdown approach was used to investigate the biofactors in Hypo-EVs. Results: Nebulization of Hypo-EVs directly alleviated airway epithelial barrier defects in asthmatic mice, as evidenced by colocalization with bronchial epithelial cells, decreased albumin concentration, and increased ZO-1 and E-cadherin expression. In vitro, Hypo-EV treatment dramatically rescued the increase in airway cell permeability, and upregulated the ZO-1 and E-cadherin protein expressions. Based on WB analysis, we found that caveolin-1 (CAV-1) was strongly enriched in Hypo-EVs. The knockdown of CAV-1 protein levels in Hypo-EVs significantly impaired Hypo-EV-mediated barrier protection in vitro and in vivo. Moreover, CAV-1 knockdown significantly abolished the beneficial effects of Hypo-EVs on airway inflammation and remodeling in asthmatic mice. In addition, we showed that IL-4/IL-13-induced airway epithelial barrier defects were mainly related to activation of STAT6 phosphorylation (p-STAT6), and overexpression of CAV-1 or Hypo-EV treatment inhibited the levels of p-STAT6 in IL-4/IL-13-induced HBE135-E6E7 cells. Conclusion: Nebulization of Hypo-EVs can attenuate airway epithelial barrier defects in asthma by delivering CAV-1 to inhibit p-STAT6 expression and may be used to treat other barrier defect diseases. Keywords: nebulization, Hypo-EVs, asthma, airway epithelial barrier, caveolin-1 Asthma is a common chronic respiratory disease that affects at least 300 million people worldwide. 1 It is characterized by airway inflammation and remodeling, which may result in small airway narrowing, exhalation dysfunction and even patient death. 2 Inhaled corticosteroids are the most basic treatment for asthma; they can provisionally control respiratory symptoms but do not focus on disease regression, additionally, their long-term use has certain side effects on general health. 3,4 Therefore, effective and safe therapeutic strategies for asthma are urgently needed. The pathogenesis of asthma has been the subject of intensive study in recent decades, and it is now widely accepted that the disruption of airway epithelial barrier (AEB) represents a key factor in the aetiology of asthma. 5,6 The AEB is constituted by adjacent bronchial epithelial cells, with junctional proteins (such as E-cadherin and ZO-1) attaching to neighbouring cells and controlling paracellular transport. In asthmatic conditions, the AEB function is impaired, as indicated by decreased junctional protein expression and increased epithelial barrier permeability, which enables external allergens to penetrate the airway submucosa, subsequently triggering the type-2 inflammation response. 7 Type-2 immune cytokines, such as interleukin-4 (IL-4) and IL-13 induce a number of processes associated with the development of airway inflammation and remodeling, including eosinophil recruitment, goblet cell hyperplasia, and extracellular ma -Abstract Truncated-

Nemo mRNA vaccination improves airway barrier function in mice with airway allergy

Condensin Smc4 Promotes Inflammatory Innate Immune Response by Epigenetically Enhancing NEMO Transcription.

Myeloid NEMO deficiency promotes tumor immunosuppression partly via MCP1-CCR2 axis

DZNep attenuates allergic airway inflammation in an ovalbumin-induced murine model

[Impact and mechanism of NEMO binding domain peptide on pulmonary inflammation and apoptosis of lung tissues in mice with acute respiratory distress syndrome]

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Esophageal epithelial deletion promotes eosinophilic esophagitis in experimental allergy mouse model

Epimedin C modulates the balance between Th9 cells and Treg cells through negative regulation of noncanonical NF-κB pathway and MAPKs activation to inhibit airway inflammation in the ovalbumin-induced murine asthma model

RSV Promotes Epithelial Neuroendocrine Phenotype Differentiation through NODAL Signaling Pathway

Environmental pollutant 3-methyl-4-nitrophenol promotes the expression of oncostatin M to exacerbate airway allergic inflammation

Nuocytes from mesenteric lymph node promote allergic responses in a mouse model

NLRP6 negatively regulates type 2 immune responses in mice

Nebulization of Hypoxic hUCMSC-EVs Attenuates Airway Epithelial Barrier Defects in Chronic Asthma Mice by Transferring CAV-1

Sensing and signaling of immunogenic extracellular RNAs restrain group 2 innate lymphoid cell-driven acute lung inflammation and airway hyperresponsiveness

Effects of Nerve Growth Factor Shrna Inhibition on Asthma Phenotypes in a Mouse Model of Asthma.

Macrophages activated by type 2 cytokines function and gene expression

Deletion of Peroxiredoxin 6 Potentiates Ova-Induced Asthma Epithelial-Mesenchymal Transition Through Egfr Pathway

Co-adjuvanting Nod2-stimulating bacteria with a TLR7 agonist elicits potent protective immunity against respiratory virus infection

T Cell Impairment Is Predictive for a Severe Clinical Course in NEMO Deficiency

Nerolidol attenuates airway inflammation and airway remodeling and alters gut microbes in ovalbumin-induced asthmatic mice

lncRNA CRNDE Affects Th17/IL-17A and Inhibits Epithelial-Mesenchymal Transition in Lung Epithelial Cells Reducing Asthma Signs